Home

Psychiatry team venom akojos Rust climate Composer

Lilly Continues Foray into Gene Therapies with $487M Akouos Buyout |  BioSpace
Lilly Continues Foray into Gene Therapies with $487M Akouos Buyout | BioSpace

Akouos Careers | Levels.fyi
Akouos Careers | Levels.fyi

Akouos Overview | SignalHire Company Profile
Akouos Overview | SignalHire Company Profile

STEM Completes Lab Fit-Out for Akouos | High-Profile Monthly
STEM Completes Lab Fit-Out for Akouos | High-Profile Monthly

Lonza to make delivery vectors for Akouos' gene therapies at Houston plant
Lonza to make delivery vectors for Akouos' gene therapies at Houston plant

Akouos Announces Gene Therapy to Treat Genetic Hearing Loss | The Hearing  Review
Akouos Announces Gene Therapy to Treat Genetic Hearing Loss | The Hearing Review

Akouos Presents Nonclinical Data Supporting the Planned Clinical  Development of AK-OTOF at ASGCT | Hearing Health & Technology Matters
Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF at ASGCT | Hearing Health & Technology Matters

Lilly's message is loud and clear: Akouos' AAV hearing loss therapy is  worthwhile | BioWorld
Lilly's message is loud and clear: Akouos' AAV hearing loss therapy is worthwhile | BioWorld

NEA on Twitter: "🎉 Congratulations, Akouos! 👏🏽🤩🚀 Akouos to be acquired  by @LillyPad: https://t.co/3qKl9lN3Wo https://t.co/UPMY69oh82" / Twitter
NEA on Twitter: "🎉 Congratulations, Akouos! 👏🏽🤩🚀 Akouos to be acquired by @LillyPad: https://t.co/3qKl9lN3Wo https://t.co/UPMY69oh82" / Twitter

AKOUOS, INC. : Termination of a Material Definitive Agreement, Completion  of Acquisition or Disposition of Assets, Notice of Delisting or Failure to  Satisfy a Continued Listing Rule or Standard; Transfer of Listing,
AKOUOS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing,

Akouos Receives FDA Clearance of its IND Application for Gene Therapy  Hearing Loss Treatment, AK-OTOF | Hearing Health & Technology Matters
Akouos Receives FDA Clearance of its IND Application for Gene Therapy Hearing Loss Treatment, AK-OTOF | Hearing Health & Technology Matters

Lilly agrees to acquire gene therapy developer Akouos for $610m
Lilly agrees to acquire gene therapy developer Akouos for $610m

Eli Lilly to buy gene therapy company Akouos for $487 mln | Reuters
Eli Lilly to buy gene therapy company Akouos for $487 mln | Reuters

About Us – Akouos
About Us – Akouos

Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

Eli Lilly's $487M Akouos buyout expands its gene therapy scope to hearing  loss - MedCity News
Eli Lilly's $487M Akouos buyout expands its gene therapy scope to hearing loss - MedCity News

Lonza, Akouos and MEE Announce Strategic Gene Therapy License Agreements on  Hearing and Balance Disorders | Technology Networks
Lonza, Akouos and MEE Announce Strategic Gene Therapy License Agreements on Hearing and Balance Disorders | Technology Networks

Lilly to acquire gene therapy company Akouos
Lilly to acquire gene therapy company Akouos

Our Focus – Akouos
Our Focus – Akouos

Akouos Just Raised $50 Million in a Series a Funding Round
Akouos Just Raised $50 Million in a Series a Funding Round

Akouos nabs meaty $105M raise, adds VC and biotech veterans to board |  Fierce Biotech
Akouos nabs meaty $105M raise, adds VC and biotech veterans to board | Fierce Biotech

Lilly to acquires hearing loss company Akouos
Lilly to acquires hearing loss company Akouos

Our Focus – Akouos
Our Focus – Akouos

Eli Lilly to buy gene therapy company Akouos for $487 mln | Reuters
Eli Lilly to buy gene therapy company Akouos for $487 mln | Reuters

S-1
S-1

About Us – Akouos
About Us – Akouos

Our Focus – Akouos
Our Focus – Akouos